Agonism of ERβ is of great current pharmaceutical interest due to a variety of observations that include decreasing survival of p53-defective cancer cells by imparing G2/M checkpoint signaling31, playing a role as a tumor suppressor of epithelial ovarian cancer32 and of gliomas33, reducing invasiveness of triple-negative breast cancer cells34, inducing cell death in acute myeloid leukemia35, and decreasing proliferation of ovarian cancer cells36. Here, TP53 is linked to triple-negative breast carcinoma.